ArticleFrontiers in microbiology2020
Genomic Analysis of Carbapenem-Resistant
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 43 citations in OpenAlex.
- Outbreak of Multidrug-Resistant (MDR) Acinetobacter baumannii ST-15 Strains Co-producing OXA-23 and OXA-58 in South America.Current microbiology · 2026Article
- ConsistentAntimicrobial agents and chemotherapy · 2026Article
- Global multi-host genomic epidemiology of Acinetobacter baumannii reveals transmission at one health interfaces.Nature communications · 2026Article
- Systematic review on genomic insights into antimicrobial resistance in ESKAPE pathogens.African journal of laboratory medicine · 2026Review
- Epidemiology and molecular typing of multidrug resistant Acinetobacter baumannii burn wound isolates from six Chinese provinces.Scientific reports · 2025Article
- ISAntimicrobial agents and chemotherapy · 2025Article
- Phylogenomic analysis of aquatic and clinical OXA-23-positiveOne health (Amsterdam, Netherlands) · 2025Article
- Global emergence ofMicrobial genomics · 2025Article
- Effect of Meropenem, Sulbactam, and Colistin Combinations on Resistance Gene Expression in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Genomic epidemiology reveals antibiotic resistance transfer and polyclonal dissemination ofAntimicrobial agents and chemotherapy · 2025Article
- The global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2025Review
- Genomic Characterization of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- β-Lactamase diversity inAntimicrobial agents and chemotherapy · 2025Article
- Genomic characterization of multidrug-resistant clinicalFrontiers in cellular and infection microbiology · 2025Article
- The fitness connection of antibiotic resistance.Frontiers in microbiology · 2025Article
- Fluoroquinolone resistance in ESKAPE pathogens: evolutionary pathways, one health transmission, and clinical surveillance.Frontiers in microbiology · 2025Review
- Cefiderocol in Combating Carbapenem-ResistantBiomedicines · 2024Review
- Genomic study ofFrontiers in microbiology · 2024Article
- Article
- International Clones of High Risk of Acinetobacter Baumannii-Definitions, History, Properties and Perspectives.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.